Volume : 12, Issue : 01, January – 2025
Title:
NEW ADVANCEMENT IN ANTIBACTERIAL RESISTANCE
Authors :
Gayatri V. Apotikar *, Sakshi R. Manekar , Shubham U. Tikait , Swati P. Deshmukh
Abstract :
The rise of antibacterial resistance speaks to one of the most noteworthy worldwide wellbeing challenges of the 21st century, driven by the abuse and abuse of anti-microbials and the fast advancement of safe pathogens. This inquire about highlights a novel progression in combating anti-microbial resistance through the integration of nanotechnology, accuracy sedate conveyance, and antimicrobial peptides. The ponder presents a modern course of bioengineered Nano carriers able of focusing on safe bacterial strains with tall specificity, minimizing collateral harm to advantageous microbiota. Moreover, the advancement of versatile antimicrobial peptides, planned to disturb bacterial films and restrain resistance components, illustrates upgraded adequacy against multidrug-resistant strains. Preparatory comes about from in vitro and in vivo models demonstrate a 90% diminishment in bacterial stack compared to routine medications, with negligible harmfulness. This breakthrough clears the way for economical, focused on treatments to relieve the spread of resistance, advertising a promising elective to conventional anti-microbial in the battle against superbugs. Encourage inquire about will investigate versatility and clinical applications to address this critical open wellbeing danger.
Keywords: Antibacterial drug resistance: – Nosocomial infection
Cite This Article:
Please cite this article in press Gayatri V. Apotikar et al., New Advancement In Antibacterial Resistance.,Indo Am. J. P. Sci, 2025; 12 (01).
Number of Downloads : 10
References:
1. Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbial Mol Biol Rev. 2010;74(3):417-33.
2. Centers for Disease Control and Prevention (CDC). Antibiotic Resistance Threats in the United States, 2019. U.S. Department of Health and Human Services, CDC; 2019.
3. Gould IM, Bal AM. New antibiotic agents in the pipeline and how they can help overcome microbial resistance. Virulence. 2013;4(2):185-91.
4. Kohanski MA, Dwyer DJ, Collins JJ. How antibiotics kill bacteria: from targets to networks. Nat Rev Microbiol. 2010;8(6):423-35.
5. Allegranzi B, Bagheri Nejad S, Combescure C, Graafmans W, Attar H, Donaldson L, et al. Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet. 2011;377(9761):228-41.
6. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P T. 2015;40(4).
7. Tomasz A. Multiple-antibiotic-resistant pathogenic bacteria. N Eng. J Med. 1994;330(17):1247-51.
8. Blevins SM, Bronze MS. Robert Koch and the ‘golden age’ of bacteriology. Int J Infect Dis. 2010;14(9):e744-e751.
9. Courvalin, P. (2006). Antibiotic Resistance: A Realistic Perspective. Clinical Microbiology and Infection, 12(s1), 2-6.
10. Reardon, S. (2014). Phage therapy gets revitalized with modern techniques. Nature, 510(7503), 15-16.
11. Ventola CL. The antibiotic resistance crisis: Part 1: Causes and threats. Pharmacy and Therapeutics. 2015;40(4):277-83.
12. Walsh FM, Amyes SG. Microbiology and drug resistance mechanisms of fully resistant pathogens. Microbiology. 2004;7:439-44.
13. Ventola CL The antibiotic resistance crisis part1: causes and threats. P T. 2015;40(4):277 83.
14. Walsh FM, Amyes SGB. Microbiology and drug resistance mechanisms of fully resistant pathogens. Microbiology. 2004;7:439–44.
15. Weinstein RA. Controlling antimicrobial resistance in hospitals: infection control and use of antibiotics. Emerg Infect Dis. 2001;7:188–92.
16. Anonymous. European Antimicrobial Resistance Surveillance System. EARSS Annual Report 2002. 2002.
17. Walsh, F.M. & Amyes, S.G.B. Microbiology and drug resistance mechanisms of fully resistant pathogens. . Microbiology 7, 439–444 (2004).
18. Weinstein RA. Controlling antimicrobial resistance in hospitals: infection control and use of antibiotics. Emerg Infect Dis. 2001;7:188–92.
19. Anonymous. European Antimicrobial Resistance Surveillance System. EARSS Annual Report 2002. 2002.
20. Hiramatsu K. Vancomycin resistance in staphylococci. Drug Resist Updat. 1998;1:135–50.
21. Jones RN, Bellow CH, Biedenbach DJ, Diehard JA, Schentag JJ. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn Microbiol Infect Dis. 1998;31(3):437–51.
22. Meka VG, Gold HS. Antimicrobial resistance to linezolid. Clin Infect Dis. 2004;39(7):1010-5.
23. Weinstein RA. Controlling antimicrobial resistance in hospitals: infection control and use of antibiotics. Emerg Infect Dis. 2001;7(2):188-92.
24. Anonymous. European Antimicrobial Resistance Surveillance System. EARSS Annual Report 2002 (2002).
25. Fridkin, S.K. Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Infect. Dis. 32, 108–115 (2001)
26. S.B. The 2000 Garrod lecture. Factors impacting on the problem of antibiotic resistance. J Antimicrobial Chemosphere. 2002;49(1):25-30.
27. M Benbrook C, Benbrook KL. Hogging it: estimates of antimicrobial abuse in livestock. Cambridge (UK): UCS Publications; 2001.
28. M, S.L. Gorbach SL. The need to improve antimicrobial use in agriculture: ecological and human health consequences. Clin Infect Dis. 2002;34(Suppl):S71–S144.
29. Levy SB, Miller RV, editors. Gene transfer in the environment. New York: McGraw Hill; 1989.
30. Schneiders T, Amyes SG, Levy SB. Role of AcrR and RamA in fluoroquinolone resistance in clinical Klebsiella pneumoniae isolates from Singapore. Antimicrobial Agents Chemother. 2007.
31. Alekshun MN, Levy SB. Regulation of chromosomally mediated multiple antibiotic resistance: the mar regulon. Antimicrobials Agents Chemother. 1997;41:2067-2075.
32. Levy SB. Antibiotic resistance: an ecological imbalance. In: Antibiotic Resistance: Origins, Evolution, and Spread. Chichester, UK: J. Wiley; 1997. P. 1-9.
33. Levy SB. Starting life resistance-free. N Engl J Med. 1990;323:335-337.S110.
34. Song JH, Hsueh PR, Chung DR, Ko KS, Kang CI, Peck KR, et al. Spread of methicillin- resistant Staphylococcus aureus between the community and hospitals in Asian countries: an r study.
35. Borg MA, de Kraker M, Scicluna E, van de Sande Bruinsma N, Tiemersma E, Monen J, et al. Prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in invasive isolates from southern and eastern Mediterranean countries.
36. Laxminarayan R, Matsoso P, Pant S, Brower C, Røttingen JA, Klugman K, et al. Access to effective antimicrobials: A worldwide challenge. 2016.
37. Barker KF. Antibiotic resistance: a current perspective. Br J Clin Pharmacol. 1999;48(2):109.
38 . Bonfiglio G, Perilli M, Stefani S, Amicosante G, Nicoletti G. Prevalence of extended spectrum β-lactamases among Enterobacteriaceae: an Italian survey. Int J Antimicrobials Agents. 2002;19(3):213-217.
39. Rashmi S, Bhuvneshwar K. Antibacterial resistance: current problems and possible solutions. Indian J Med Sci. 2005;59:120-129.
40. Buynak JD. The discovery and development of modified penicillin- and cephalosporin-derived β-lactamase inhibitors. Curr Med Chem. 2004;11(14):1951-1964.